Physician profile
John E Cattaneo
NPI 1497786057
$812.54
in general payments reported to CMS, 2019-2025
12 companies · $271 in 2025
The $271 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.08 · 2020: $17.68 · 2021: $176 · 2023: $122 · 2024: $204 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $596.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $152.82 | 2025 | Vyvgart |
| Genentech USA, INC. | $121.70 | 2023 | Ocrevus |
| Tg Therapeutics, INC. | $117.93 | 2025 | |
| Ucb, INC. | $114.32 | 2024 | Fintepla |
| Genentech, INC. | $71.44 | 2024 | Ocrevus |
| Medtronic, INC. | $53.58 | 2021 | |
| Abbvie INC. | $41.43 | 2021 | |
| Livanova USA, INC. | $40.76 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $31.14 | 2021 | |
| Abbott Laboratories | $26.19 | 2021 | |
| Biogen, INC. | $23.33 | 2021 | |
| Amneal Pharmaceuticals LLC | $17.90 | 2024 | Ongentys 50mg Capsules 30 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cattaneo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.